Editing CSL Limited (section)

== Vaccines ==
{{flu}}

=== A/H1N1 2009 pandemic ===
{{See also|2009 swine flu pandemic in Australia}}
CSL's vaccine for [[Influenza A virus subtype H1N1|swine flu]], the world's first, was approved in September 2009 for use by people over age 10.<ref>{{cite web
 |title=Panvax H1N1 Approval For Registration For Use in Australia by Therapeutic Goods Administration 
 |url=http://www.csl.com.au/s1/cs/auhq/1196562649899/news/1249870443804/prdetail.htm 
 |archive-url=https://web.archive.org/web/20090925175938/http://www.csl.com.au/s1/cs/auhq/1187378853299/news/1249870443804/prdetail.htm
 |publisher=CSL Limited 
 |location=Melbourne, Australia 
 |date=18 September 2009 
 |archive-date=25 September 2009
 |access-date=26 September 2009 
 |quote=CSL Biotherapies, a subsidiary of CSL Limited, Australia's leading biopharmaceutical company, can today confirm that its vaccine against the pandemic (H1N1) 2009 influenza or 'swine flu' has been approved registration for use in people aged 10 years and over.
 |url-status=live 
}}</ref> The federal government ordered 21{{nbsp}}million doses of vaccine for Australians.<ref>{{Cite news|last=Tran|first=Mark|date=2009-07-22|title=First human trials of swine flu vaccine begin in Australia|language=en-GB|work=The Guardian|url=https://www.theguardian.com/world/2009/jul/22/swine-flu-australia-vaccine-tests|access-date=2020-09-07|issn=0261-3077}}</ref> [[CSL Behring|CSL]] also provided vaccines for customers in Singapore and the US.

On 28 September 2010, the Australian [[Therapeutic Goods Administration]]  (TGA) conducted an analysis of [[febrile convulsions]] following immunisation in children following monovalent pandemic [[Influenza A virus subtype H1N1|H1N1]] vaccine (Panvax/Panvax Junior, CSL).<ref>{{Cite web |last=Administration |first=Australian Government Department of Health Therapeutic Goods |date=2010-09-28 |title=Analysis of febrile convulsions following immunisation in children following monovalent pandemic H1N1 vaccine (Panvax/Panvax Junior, CSL) |url=https://www.tga.gov.au/alert/analysis-febrile-convulsions-following-immunisation-children-following-monovalent-pandemic-h1n1-vaccine-panvaxpanvax-junior-csl |access-date=2022-07-25 |website=Therapeutic Goods Administration (TGA) |language=en}}</ref>

A paper published in the Medical Journal of Australia provides a possible reason for CSL's 2010 flu vaccine causing febrile convulsions in children. The authors hypothesise that suboptimal use of the detergent called [[deoxycholate]] – used in the manufacturing process by CSL (one of the few vaccine manufacturers that use it) – to split the flu virus from its membrane may be at fault.<ref>{{cite journal|title=Adverse events associated with 2010 CSL and other inactivated influenza vaccines|pmid=21929484|doi=10.5694/mja11.10941|journal=The Medical Journal of Australia|volume=195|issue=6|date=19 September 2011|pages=318–320|first1=Heath A|last1=Kelly|first2=Danuta M|last2=Skowronski|first3=Gaston|last3=De Serres|first4=Paul V|last4=Effler|s2cid=9389146 }}</ref>

=== COVID-19 pandemic ===
{{See also|COVID-19 pandemic in Australia}}
On 7 September 2020, CSL signed agreements with the Australian government to supply the University of Queensland vaccine ([[V451 vaccine|V451]]) and to manufacture (with [[AstraZeneca]]) the [[University of Oxford|Oxford University]] vaccine ([[AZD1222]]), which would yield nearly 85 million doses for Australians. The agreement was contingent on the future success of clinical trials of these vaccines. Most of the manufacture would occur in Melbourne, Australia.<ref>{{Cite web|date=7 September 2020|title=CSL to manufacture and supply University of Queensland and Oxford University vaccine candidates for Australia|url=https://www.csl.com/news/2020/20200907-csl-to-manufacture-and-supply-uq-and-ou-vaccine-candidates-for-australia|access-date=2020-09-07|website=csl.com|language=en-US}}</ref><ref>{{Cite web|date=7 September 2020|title=Australia secures onshore manufacturing agreements for two COVID-19 vaccines {{!}} Prime Minister of Australia|url=https://www.pm.gov.au/media/australia-secures-onshore-manufacturing-agreements-two-covid-19-vaccines|access-date=2020-09-07|website=pm.gov.au|archive-date=7 September 2020|archive-url=https://web.archive.org/web/20200907043720/https://www.pm.gov.au/media/australia-secures-onshore-manufacturing-agreements-two-covid-19-vaccines|url-status=dead}}</ref>

On 11 December 2020, after a high percentage of the University of Queensland vaccine trial participants returned "false positive" results for HIV, it was decided that vaccine development will not proceed to Phase 2/3 trials.<ref>{{Cite web|title=Update on The University of Queensland COVID-19 vaccine|url=https://wcsecure.weblink.com.au/pdf/CSL/02320942.pdf|publisher=CSL Limited|url-status=live|archive-url=https://web.archive.org/web/20201211104422/https://wcsecure.weblink.com.au/pdf/CSL/02320942.pdf |archive-date=11 December 2020 }}</ref>

On 23 March 2021, the [[Therapeutic Goods Administration]] provisionally approved the first batches, numbering 832,000 doses, of the [[Oxford–AstraZeneca COVID-19 vaccine]] manufactured by CSL in its plant in [[Broadmeadows, Victoria]]. The Australian Government has contracted CSL to produce 50 million doses of the vaccine.<ref>{{Cite web|date=2021-03-23|title=National medical regulator approves 800,000 Australian-made doses of AstraZeneca vaccine|url=https://www.abc.net.au/news/2021-03-23/therapeutic-goods-administration-astrazeneca-vaccine-approved/100024730|access-date=2021-04-09|publisher=Australian Broadcasting Corporation|language=en-AU}}</ref>